Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2022.0311

Original Article

Impact of molecular subtypes on 18 Fluorodeoxyglucose Positron emission Tomography/Computed Tomography (18 FDG PET/CT) results in metastatic breast cancer.

Ghada Mohamed Ahmad Zahir, Hanan Ahmed Wahba, Saleh Mansour Ta-Ema, Eman Abd-ElkareemToson.

Affiliation:
Clinical Oncology & Nuclear Medicine Faculty of Medicine, Mansoura University, Egypt.

E-mail: drghada3888@gmail.com

Abstract
Background
Metastatic breast cancer is considered an unrecoverable disease, about 12% of patients diagnosed with breast cancer develop metastatic disease. Metastatic breast cancer is associated with a poor prognosis: 26% is the 5-year survival rate. Positron Emission Tomography - Computed Tomography (PET CT) is now more frequently used in breast cancer staging and follow-up. There is a strong relation between hormonal receptors in the tumor tissue and the response to hormone therapy and chemotherapy. Our prospective study includes 40 female patients with metastatic breast cancer who were treated in the Department of Clinical Oncology & Nuclear Medicine at Mansoura University Main Hospitals and Health Insurance Institute. This study aims to see how different molecular subtypes affect fluorodeoxyglucose (FDG) avidity in different metastatic lesions in patients with metastatic breast cancer who are undergoing PET/CT, as well as to detect therapy response using PET-CT in metastatic breast cancer concerning different molecular subtypes.
Results
The standardized uptake value (SUV) post-treatment value was statistically significantly lower in luminal A molecular subtype for bone metastases, and in luminal B+ molecular subtype for lung metastases, and a statistically significantly higher SUV post-treatment value in luminal B- molecular subtype for bone metastases. There is no other statistically significant difference in other luminal subtypes in different metastatic sites. There was a statistically significant difference in treatment response (progressive vs. non-progressive) between the four molecular subtypes as in luminal A, and luminal B+ subtypes, none of the patients' progressive disease (PD). In luminal B-, 70% had PD (54% of PD had luminal B- subtype). In basal-like, 75% had PD (46% of PD had basal-like subtype).
Conclusions
FDA avidity in various metastatic lesions in patients with breast cancer undergoing PET/CT is affected by molecular subtyping (Luminal A, Luminal B+, Luminal B-, Basal-like). The poorest prognosis is associated with the basal-like subtype, whereas the most excellent prognosis is associated with the Luminal A subtype.

Keywords: Molecular subtypes, 18 FDG PET/CT, Metastatic breast cancer.

(Citation: Gastric & Breast Cancer 2022; 17(1): 12-26)

Back

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 1 February 2022